<DOC>
	<DOCNO>NCT00113646</DOCNO>
	<brief_summary>The purpose study determine recipient non-myeloablative ex-vivo T-cell deplete peripheral blood ( PBSC ) stem cell transplantation use mismatch related donor less severe graft versus host disease ( GVHD ) , transplant related mortality , less graft failure compare alternative haploidentical stem cell transplantation .</brief_summary>
	<brief_title>Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation Hematologic Malignancies</brief_title>
	<detailed_description>One major obstacle advancement role bone marrow transplant ( BMT ) hematological malignancy graft-versus-host-disease ( GVHD ) , best prevent remove T-cells donor stem cell product . However , previous experience T-cell depletion associate increased rate engraftment failure leukemic relapse . Another obstacle large fraction leukemia lymphomas afflict old patient prone GVHD co-morbid condition prevent candidate BMT . This trial use non-myeloablative condition regimen cyclophosphamide , MEDI-507 , fludarabine , thymic irradiation follow T-cell deplete PBSC infusion . Cyclosporine use GVHD prophylaxis , taper begin day 35 . Data mouse model previous clinical trial demonstrate approach induce mixed chimerism without GVHD , potential conversion mixed chimerism full donor hematopoiesis follow donor leukocyte infusion .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>Disease Status : NHL , HD , MM chemorefractory relapse ; CLL Rai stage III IV , lymphocyte double time 6 month , stage I/II resistant &gt; 2 cycle chemotherapy regimen ; CML accelerate blast phase ; MDS lifethreatening cytopenia ; patient previous autologous allogeneic bone marrow stem cell transplant ; hematological disorder allogeneic transplant appropriate risk conventional transplantation consider unacceptably high . estimate disease free survival less one year ECOG performance status 0 , 1 , 2 HLA 1 3 mismatch ( A , B , DR locus ) relate donor Cardiac disease : symptomatic congestive heart failure , ejection fraction &lt; 45 % , active angina pectoris uncontrolled hypertension . Pulmonary disease : severe chronic obstructive lung disease , symptomatic restrictive lung disease , correct DLCO &lt; 50 % Renal disease : serum creatinine &gt; 2.0 mg/dl creatinine clearance &lt; 50 ml/min Hepatic disease : serum bilirubin &gt; 2.0 mg/dl alkaline phosphate , SGPT SGOT &gt; 3 x normal Neurologic disease : symptomatic leukoencephalopathy , active CNS malignancy neuropsychiatric abnormality believe preclude transplantation HIV antibody Hepatitis B surface antigen positivity Uncontrolled infection Presence HAMA HAHA patient previously treat monoclonal antibody therapy receive product preparation involve monoclonal antibody affinity step</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Non-Myeloablative</keyword>
	<keyword>T-cell Depleted</keyword>
	<keyword>Mismatched</keyword>
	<keyword>Stem Cell Transplantation</keyword>
</DOC>